Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001.

Trial Profile

Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An Open Label, Stratified, Single-arm Phase II Study of Bevacizumab and RAD001.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary)
  • Indications Liver cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2012 Actual patient number added 33 according to ClinicalTrials.gov.
    • 27 Apr 2012 Actual end date changed from 1 May 2011 to Apr 2012 added as reported by ClinicalTrials.gov record.
    • 28 Mar 2012 Actual end date (1 May 2011) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top